. 2012 May 23;75(1):118–128. doi: 10.1111/j.1365-2125.2012.04334.x

Table 2.

GSK679586 plasma pharmacokinetic parameters after single intravenous infusion of GSK679586 in healthy subjects

	0.005 mg kg⁻¹	0.05 mg kg⁻¹	0.5 mg kg⁻¹	2.5 mg kg⁻¹	10 mg kg⁻¹
	(n = 3)	(n = 3)	(n = 6)	(n = 6)	(n = 6)
AUC(0,∞) (mg ml⁻¹ h)	–	0.404 (6.4)	4.04 (10.5)	26.6 (10.9)	76.0 (28.6)
AUC(0,∞) (mg ml⁻¹ h)	–	n = 2	n = 5	n = 6	n = 6
AUC(0,week 4) (mg ml⁻¹ h)	–	0.232 (1.7)	2.56 (11.7)	16.4 (5.0)	43.0 (14.6)
AUC(0,week 4) (mg ml⁻¹ h)	–	n = 2	n = 6	n = 6	n = 6
C_max (µg ml⁻¹)	0.130 (7.6)	0.883 (0.9)	11.1 (14.4)	87.4 (15.1)	197 (22.1)
C_max (µg ml⁻¹)	n = 2	n = 3	n = 6	n = 6	n = 6
t_max (h)	1.25 (0.50, 2.00)	4.00 (2.00, 4.00)	2.04 (1.00, 12.0)	3.00 (2.00, 12.0)	2.00 (1.00, 4.00)
t_max (h)	n = 2	n = 3	n = 6	n = 6	n = 6
t_1/2 (h)	–	540 (8.1)	467 (20.0)	591 (24.2)	578 (39.4)
t_1/2 (h)	–	n = 2	n = 5	n = 6	n = 6
CL (ml day⁻¹ kg⁻¹)	–	2.98 (6.3)	2.98 (10.5)	2.25 (10.9)	3.17 (28.6)
CL (ml day⁻¹ kg⁻¹)	–	n = 2	n = 5	n = 6	n = 6
V_ss (ml kg⁻¹)	–	94.6 (1.2)	83.2 (9.7)	67.3 (13.9)	105 (19.3)
V_ss (ml kg⁻¹)	–	n = 2	n = 5	n = 6	n = 6

Values represent median (range) for t_max and geometric mean (between subject coefficient of variation, CVb%) for all other parameters.

For the 0.005 mg kg⁻¹ dose group, AUC(0,∞), AUC(0,week 4), t_1/2, CL, and V_ss were not determined because none of the patients had sufficient plasma concentration data for calculation of these parameters. % AUC extrapolated was below 20% except in three subjects, two at the 0.05 mg kg⁻¹ dose (20% and 26%) due to LLQ censoring and one subject at the 10 mg kg⁻¹ dose (25%). AUC(0,∞), area under the plasma concentration–time curve (AUC) from time zero extrapolated to infinity; AUC(0,week 4), AUC from time zero to week 4; C_max, maximum observed plasma concentration; t_max, time of maximum observed plasma concentration; t_1/2, terminal phase half-life; CL = systemic clearance; V_ss, volume of distribution at steady-state.